The field of kidney cancer has dramatically evolved over the past several years due to notable advances. Most importantly, systemic treatment options have expanded to include combination regimens for advanced disease and expansion of treatment options in the adjuvant setting. Additionally, surgical management has evolved towards nephron-sparing and minimally invasive approaches for treatment of localized disease; the role of surgery and focal therapy are changing for patients with advanced disease. While kidney cancer is a common malignancy in both men and women worldwide, mortality has improved over time given advancements in modern oncology. This book provides a comprehensive, state-of-the art review of the field, and serves as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The book reviews new data about systemic treatment options for patients with advanced disease including strategies in the treatment naïve and post frontline setting. It covers new data regarding perioperative and adjuvant treatments for patients with localized disease and will highlight novel targets and treatments under development. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain will also be discussed. Additionally, the book discusses the evolving role of alternative focal approaches including radiation therapy for patients with advanced disease. This text serves as a very useful resource for physicians and researchers dealing with and interested in this challenging malignancy. Specifically, urologists, medical oncologists, radiation oncologists, basic science and translational researchers with interest in RCC, fellows in urologic oncology, upper level residents training in urology and medical oncology, and pharmaceutical partners interested in RCC will benefit most significantly. Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma will provide a concise yet comprehensive summary of strategies for sequencing therapies that will help guide patient care and stimulate investigative efforts.

• 关于产品：
• ● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
• ● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
• ● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
• 
  关于退换货：
• 由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
• 由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
• ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
  并请在工作日通过电话400-008-1110联系我们。
• 签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
• ● 缺页/错页/错印/脱线
• 
  关于发货时间：
• 一般情况下：
• ●【现货】 下单后48小时内由北京（库房）发出快递。
• ●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
• ● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
• ● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
• 
  关于到货时间：
• 由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
• ● 主要城市一般2-4天
• ● 偏远地区一般4-7天
• 
  关于接听咨询电话的时间：
• 010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
• 其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
• 
  关于快递：
• ● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。